ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 840,73
-0,12%
DAX
18 557,27
-0,48%
Brent Oil
79,265
-0,77%
Bitcoin
69 261,00
-2,12%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aimmune Therapeutics Inc (AIMT)

  7. Aimmune Therapeutics Inc (AIMT) Actualités

AIMT

Aimmune Therapeutics (AIMT)

Aimmune Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AIMT
DateHeureSourceTitreSymboleSociété
25/02/202115h00Business WireAimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 YearsNASDAQ:AIMTAimmune Therapeutics Inc
16/02/202122h19Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AIMTAimmune Therapeutics Inc
21/12/202007h15Business WireEuropean Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EUNASDAQ:AIMTAimmune Therapeutics Inc
23/10/202019h12Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:AIMTAimmune Therapeutics Inc
19/10/202023h05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AIMTAimmune Therapeutics Inc
14/10/202022h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AIMTAimmune Therapeutics Inc
13/10/202023h32Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AIMTAimmune Therapeutics Inc
13/10/202023h30Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AIMTAimmune Therapeutics Inc
13/10/202016h49Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:AIMTAimmune Therapeutics Inc
13/10/202016h45Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:AIMTAimmune Therapeutics Inc
13/10/202016h45Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:AIMTAimmune Therapeutics Inc
13/10/202015h15Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:AIMTAimmune Therapeutics Inc
13/10/202008h15Dow Jones NewsNestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With SubsidiaryNASDAQ:AIMTAimmune Therapeutics Inc
05/10/202023h27Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:AIMTAimmune Therapeutics Inc
02/10/202014h45InvestorWireLife-Saving Advancements, Treatments Delivered by Companies Invested in InnovationNASDAQ:AIMTAimmune Therapeutics Inc
23/09/202013h00GlobeNewswire Inc.Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare CompaniesNASDAQ:AIMTAimmune Therapeutics Inc
14/09/202023h28Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:AIMTAimmune Therapeutics Inc
14/09/202023h17Edgar (US Regulatory)Statement of Ownership: Private Transaction (sc 13e3)NASDAQ:AIMTAimmune Therapeutics Inc
14/09/202023h17Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:AIMTAimmune Therapeutics Inc
14/09/202007h15PR Newswire (US)Nestlé commences tender offer for Aimmune Therapeutics, Inc.NASDAQ:AIMTAimmune Therapeutics Inc
01/09/202009h02Dow Jones NewsNestlé Buys Biopharma Maker Of Peanut-Allergy Treatment -- WSJNASDAQ:AIMTAimmune Therapeutics Inc
31/08/202023h13Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:AIMTAimmune Therapeutics Inc
31/08/202018h01Business WireALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aimmune Therapeutics, Inc.NASDAQ:AIMTAimmune Therapeutics Inc
31/08/202012h50Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:AIMTAimmune Therapeutics Inc
31/08/202010h24Dow Jones NewsNestlé Moves Further Into Health, Buying Peanut-Allergy Treatment Maker -- UpdateNASDAQ:AIMTAimmune Therapeutics Inc
31/08/202008h16Dow Jones NewsNestle Health Science to Acquire Aimmune Therapeutics at $2.6 Billion ValuationNASDAQ:AIMTAimmune Therapeutics Inc
31/08/202007h15Business WireAimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health ScienceNASDAQ:AIMTAimmune Therapeutics Inc
24/08/202014h30Business WireLargest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance & Fear of Accidental Peanut Alle...NASDAQ:AIMTAimmune Therapeutics Inc
07/08/202014h00Business WireAimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceNASDAQ:AIMTAimmune Therapeutics Inc
31/07/202012h26Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AIMTAimmune Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AIMT

Dernières Valeurs Consultées

NASDAQ
AAXXBXX
Morgan Stanley Bank Na P...
COIN
TTUMBTC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés